| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 05/10/2007 | WO2003076567A3 Heterologous g-csf fusion proteins |
| 05/10/2007 | WO2002051860A3 Synthetic peptide composition as immunogens for prevention of urinary tract infection |
| 05/10/2007 | US20070107075 Disruptions in GABA Receptor RHO2 Subunit, Methods and Uses Thereof |
| 05/10/2007 | US20070107073 Use of secreted protein products for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome |
| 05/10/2007 | US20070106068 Nucleotide sequences coding Zcytor16 specific immunoglobulin for use in prevention and treatment of nervous system, inflammatory and autoimmune disorders |
| 05/10/2007 | US20070106064 Solid phase method for synthesis peptide-spacer-lipid conjugates, conjugates synthesized thereby and targeted liposomes containing the same |
| 05/10/2007 | US20070106062 Attenuated vif DNA immunization cassettes for genetic vaccines |
| 05/10/2007 | US20070105933 Amino alcohol compounds |
| 05/10/2007 | US20070105913 Alkynyl aryl carboxamides |
| 05/10/2007 | US20070105894 Combination of at least two compounds selected from an AT1-receptorantagonist or an ACE inhibitor or a HMG-Co-A reductase inhibitor |
| 05/10/2007 | US20070105808 Inhibition of histone deacetylase |
| 05/10/2007 | US20070105802 Compositions and methods for modulating and monitoring neurotransmitter receptor populations |
| 05/10/2007 | US20070105796 Method for inhibiting telomerase activity and inhibitor thereof |
| 05/10/2007 | US20070105794 Immunotherapy |
| 05/10/2007 | US20070105786 Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents |
| 05/10/2007 | US20070105785 Methods of treating non-inflammatory gastrointestinal tract disorders using Cav2.2 subunit calcium channel modulators |
| 05/10/2007 | US20070105784 Substituted quinolines for the treatment of cancer |
| 05/10/2007 | US20070105783 Process for the manufacture of peptide facilitators of reverse cholesterol transport |
| 05/10/2007 | US20070105782 Protectant Combinations for Reducing Toxicities |
| 05/10/2007 | US20070105781 Inhibitors of serine proteases |
| 05/10/2007 | US20070105780 Therapeutic agent for iNOS generating illness |
| 05/10/2007 | US20070105779 Isolated, ssx-2 and ssx-2 related peptides useful as hla binders and ctl epitopes, and uses thereof |
| 05/10/2007 | US20070105778 Methods of screening molecular libraries and active molecules identified thereby |
| 05/10/2007 | US20070105777 For detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells |
| 05/10/2007 | US20070105776 Inhibiting signaling by inhibiting palmitoylation; purified in presence of detergent to maintain solubility; maintenance and growth of stem cells, tissue regeneration |
| 05/10/2007 | US20070105775 Methods for fusion polypeptide delivery into a cell |
| 05/10/2007 | US20070105774 Use of calcitonin and calcitonin-like peptides to treat and prevent multiple sclerosis |
| 05/10/2007 | US20070105773 Pharmaceutical composition comprising TrkAIg2 for use in the prevention and/or treatment of cancer |
| 05/10/2007 | US20070105772 Induction of Apoptosis by Cellular Stress |
| 05/10/2007 | US20070105771 Anti-CD26 antibodies and methods of use thereof |
| 05/10/2007 | US20070105770 Transglutaminase mediated conjugation of peptides |
| 05/10/2007 | US20070105769 Methods of treating tissue defects |
| 05/10/2007 | US20070105768 Dry recombinant human alpha 1-antitrypsin formulation |
| 05/10/2007 | US20070105767 Modulation of the interaction of muc1 with muc1 ligands |
| 05/10/2007 | US20070105766 Modulators of the abc transporter family and methods for their use |
| 05/10/2007 | US20070105765 Compositions comprising a fragment of the herpesviral protein vp22 for delivery of substances to cells |
| 05/10/2007 | US20070105764 Fusion protein for controlling production of proteins in bioreactor: cellular therapy (somatic gene therapy); antiviral therapies |
| 05/10/2007 | US20070105763 Connective tissue derived polypeptides |
| 05/10/2007 | US20070105762 Non-activated polypeptides having a function of tissue regeneration and method for preparing the same |
| 05/10/2007 | US20070105761 Methods, compositions, and kits for the treatment of opthalmic disorders |
| 05/10/2007 | US20070105760 Process for the preparation of echinocandin derivatives |
| 05/10/2007 | US20070105759 Melanocortin receptor 4 (mc4) agonists and their uses |
| 05/10/2007 | US20070105758 Vancomycin formulations having reduced amount of histamine |
| 05/10/2007 | US20070105757 Vancomycin formulations having reduced amount of histamine |
| 05/10/2007 | US20070105756 Vancomycin formulations having reduced amount of histamine |
| 05/10/2007 | US20070105755 One pot desialylation and glycopegylation of therapeutic peptides |
| 05/10/2007 | US20070105754 Pharmaceutical composition to prevent and treat epithelial wounds, immunomodulating pharmaceutical composition, pharmaceutical composition, insecticide, insecticide composition insecticide use of lectin KM+ to treat cicatrizations, use of lectin KM+ to prepare immunomodulating medicament, use of lectin KM+ to prepare anti-bacterial medicament, use lectin KM+ to prpare anti-viral medicament, use of lectin KM+ to prepare anti-parasite medicament, use of lectin KM+ to prepare anti-fungal medicament, use of lectin KM+ to prepare anti-parasite medicament expression method, DNA vector, recombinant |
| 05/10/2007 | US20070105753 Use of dipyridamole or mopidamole for treatment and prevention of thrombo-embolic diseases and disorders caused by excessive formation of thrombin and/or by elevated expression of thrombin receptors |
| 05/10/2007 | US20070105752 Inhibition of the SRC kinase family pathway as a method of treating HBV infection and hepatocellular carcinoma |
| 05/10/2007 | US20070105751 Administering a NF- kappa B inhibitor in conjunction with the administration of a chemotherapeutic agent, whereby the cytotoxic effect of said chemotherapeutic agent is increased |
| 05/10/2007 | US20070105750 Novel plasma protein affinity tags |
| 05/10/2007 | US20070105207 Aggrecanase structure |
| 05/10/2007 | US20070105191 Capable of inducing chondrocyte proliferation; Chinese Hamster Ovary, an Escheria coli or a yeast host cell with an expression vector |
| 05/10/2007 | US20070105171 Human Protease Molecules |
| 05/10/2007 | US20070105143 Novel bHLH type transcription factor genes |
| 05/10/2007 | US20070105135 Charged compounds comprising a nucleic acid binding moiety and uses therefor |
| 05/10/2007 | US20070105127 DNA libraries comprising vector constructs coding glycosylation enzymes and organelle targeting signal sequences for use in modifying exogenously expressed polypeptides |
| 05/10/2007 | US20070105122 Primers for synthesizing full-length cDNA and their use |
| 05/10/2007 | US20070105104 Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor ltb4 (ltb4) |
| 05/10/2007 | US20070104809 Composition comprising a bacteriocin and an extract from a plant of the labiatae family |
| 05/10/2007 | US20070104794 Enzyme granules |
| 05/10/2007 | US20070104793 Process for making ceramic, mineral, and metal beads from powder |
| 05/10/2007 | US20070104777 Targeted liposomal drug delivery system |
| 05/10/2007 | US20070104759 Sustained release inserts; mixture of thermoplastic polyester, solvent and leuprolide acetate; prostate cancer |
| 05/10/2007 | US20070104756 Obesity controlling method |
| 05/10/2007 | US20070104731 Helicobacter proteins and vaccines |
| 05/10/2007 | US20070104725 Use of modified extracellular matrix proteins in diagnosis and treatment of atherosclerosis |
| 05/10/2007 | US20070104724 Attaching substances to microorganisms |
| 05/10/2007 | US20070104723 Treatment of fibrotic disease |
| 05/10/2007 | US20070104720 Novel serpentine transmembrane antigens expressed in human cancers and uses thereof |
| 05/10/2007 | US20070104719 Caspase Activated Prodrugs Therapy |
| 05/10/2007 | US20070104718 Gene BRCC-1 and diagnostic and therapeutic uses thereof |
| 05/10/2007 | US20070104713 Nogo receptor homologs |
| 05/10/2007 | US20070104712 Treatment of Inflammatory Bowel Disease with IFN-Gamma Inhibitors |
| 05/10/2007 | US20070104711 Using tumor necrosis factor inhibitor as therapeutic agent in treatment of spinal cord injury and nervous system disorders |
| 05/10/2007 | US20070104708 Compositions, methods, and kits relating to resistin |
| 05/10/2007 | US20070104707 using compounds that increase endothelial nitric oxide synthase levels to treat pre-eclampsia and eclampsia |
| 05/10/2007 | US20070104706 for encapsulating malignant tumor tissues; melanoma or lung cancer |
| 05/10/2007 | US20070104705 freeze dried or aqueous solution of thrombin, sucrose, mannitol, sodium chloride, calcium chloride, a surfactant or high molecular weight polyethylene glycol and buffers, used in surgery |
| 05/10/2007 | US20070104704 Erythropoietin receptor peptide formulations and uses |
| 05/10/2007 | US20070104703 Compositions and methods of using chondroitinase ABCI mutants |
| 05/10/2007 | US20070104702 Method for treating diseases associated with changes of qualitative and/quantitative composition of blood extracellular dna |
| 05/10/2007 | US20070104701 Method for stabilizing reduced coenzyme Q10 |
| 05/10/2007 | US20070104699 Compositions for and methods of granzyme B inhibition |
| 05/10/2007 | US20070104696 Use of cell lines to produce active therapeutic proteins |
| 05/10/2007 | US20070104684 Ocular gene therapy |
| 05/10/2007 | US20070104683 Composition and methods for affecting metallocorrinoid uptake |
| 05/10/2007 | US20070104682 Composition comprising interferon (IFN), buffer, 2-hydroxypropyl-beta-cyclodextrin ("HPBCD"), isotonicity agents and an antioxidant; enhancing cytokine shelf-life at room temperature |
| 05/10/2007 | US20070104681 Inhibits Interleukin T Cell Inducible Factors (IL-TIF/IL-22)'s effect on cells |
| 05/10/2007 | US20070104680 Antibodies to natural killer stimulatory factor |
| 05/10/2007 | US20070104679 Induction of differentiation of stem cells, and control of differentiation potency of stem cells |
| 05/10/2007 | DE102006048362A1 Composition, useful to treat and/or protect disease condition e.g. circulatory disorder, comprises an active substance combination of isoflavone or isoflavone glycoside and a peptide derivative |
| 05/10/2007 | CA2632207A1 Use of calcitonin for the treatment of ra |
| 05/10/2007 | CA2629895A1 Stable formulations containing enhancing proportions of gamma- and alpha-interferons |
| 05/10/2007 | CA2628477A1 Inhibition of autophagy genes in cancer chemotherapy |
| 05/10/2007 | CA2627875A1 Combinations comprising sorafenib and interferon for the treatment of cancer |
| 05/10/2007 | CA2627566A1 Methods for the use of branched chain amino acids |
| 05/10/2007 | CA2626868A1 Novel protein transduction domains and uses therefor |
| 05/10/2007 | CA2626866A1 Use of vaccines for the treatment/ prevention of the transmission of influenza pathogens between species |
| 05/10/2007 | CA2625106A1 Platelet aggregation inhibitor composition |